亚盛医药-B今日盘中大涨5.32%,引起市场广泛关注。这一上涨主要源于公司新药研发进展利好以及机构看好公司发展前景。
新药进展方面,亚盛医药的核心产品APG-2575已在国内递交上市申请,并正在推进海外III期临床试验。另一款核心产品耐立克则已在国内上市,并获得武田制药全球权益授权,开启重磅合作。公司新药研发进展顺利,并获得重大市场机会,这为其未来业绩增长带来强劲动力。
机构评级方面,东吴证券发布报告看好该股,预计2025年公司销售收入有望翻倍。由于亚盛医药聚焦于血液系统恶性肿瘤领域,在该细分市场具有较强的竞争优势,因此预期未来业绩将保持高速增长,支撑股价上行。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.